Truncation and pathogenic mutations facilitate the formation of intracellular aggregates of TDP-43

Takashi Nonaka1,*, Fuyuki Kametani1, Tetsuaki Arai2, Haruhiko Akiyama2 and Masato Hasegawa1,*

1Department of Molecular Neurobiology and 2Department of Psychogeriatrics, Tokyo Institute of Psychiatry, Tokyo Metropolitan Organization for Medical Research, 2-1-8 Kamikitazawa, Setagaya-ku, Tokyo 156-8585, Japan

Received April 5, 2009; Revised May 27, 2009; Accepted June 8, 2009

TAR DNA binding protein of 43 kDa (TDP-43) is a major component of the ubiquitin-positive inclusions found in the brain of patients with frontotemporal lobar degeneration (FTLD-U) and amyotrophic lateral sclerosis (ALS). Here, we report that expression of TDP-43 C-terminal fragments as green fluorescent protein (GFP) fusions in SH-SY5Y cells results in the formation of abnormally phosphorylated and ubiquitinated inclusions that are similar to those found in FTLD-U and ALS. Co-expression of DsRed-tagged full-length TDP-43 with GFP-tagged C-terminal fragments of TDP-43 causes formation of cytoplasmic inclusions positive for both GFP and DsRed. Cells with GFP and DsRed positive inclusions lack normal nuclear staining for endogenous TDP-43. These results suggest that GFP-tagged C-terminal fragments of TDP-43 are bound not only to transfected DsRed-full-length TDP-43 but also to endogenous TDP-43. Endogenous TDP-43 may be recruited to cytoplasmic aggregates of TDP-43 C-terminal fragments, which results in the failure of its nuclear localization and function. Interestingly, expression of GFP-tagged TDP-43 C-terminal fragments harboring pathogenic mutations that cause ALS significantly enhances the formation of inclusions. We also identified cleavage sites of TDP-43 C-terminal fragments deposited in the FTLD-U brains using mass spectrometric analyses. We propose that generation and aggregation of phosphorylated C-terminal fragments of TDP-43 play a primary role in the formation of inclusions and resultant loss of normal TDP-43 localization, leading to neuronal degeneration in TDP-43 proteinopathy.

INTRODUCTION

Progressive neuronal loss and abnormal protein deposits as intracellular inclusions are neuropathological features of the majority of neurodegenerative disorders, as exemplified by tau in Alzheimer’s disease (AD), alpha-synuclein in Parkinson’s disease (PD) and expanded polyglutamine gene products in CAG repeat diseases. Conformational changes, post-translational modifications or subcellular mislocalization of these normally highly soluble proteins results in the formation of abnormal protein aggregates or inclusions. It is important to establish the molecular mechanisms through which these proteins are converted to abnormal aggregates in neurons or glial cells in order to understand the pathogenesis of these diseases and to develop evidence-based, fundamental therapies.

Frontotemporal lobar degeneration with ubiquitinated inclusions (FTLD-U) and amyotrophic lateral sclerosis (ALS) are well-known neurodegenerative disorders. FTLD is the second most common form of cortical dementia in the population below the age of 65 years (1). ALS is the most common of the motor neuron diseases, being characterized by progressive weakness and muscular wasting, resulting in death within a few years. Ubiquitin (Ub)-positive inclusions are found as a pathological hallmark in brains of FTLD-U and ALS patients, as well as in AD and PD, but the major component of these inclusions had remained unknown. TAR-DNA binding protein of 43 kDa (TDP-43) has been identified as a major protein component of Ub-positive inclusions in FTLD-U and ALS brains (2,3). In 2008, mutations in the TDP-43 gene were discovered in familial

*To whom correspondence should be addressed. Tel: +81 333045701; Fax: +81 333298035; Email: nonakat@prit.go.jp (T.N.)/masato@prit.go.jp (M.H.)

© The Author 2009. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org
and sporadic cases of ALS (4–8), clearly indicating that abnormality of TDP-43 protein causes neurodegeneration. Very recently, it was also reported that two TDP-43 mutations were found in FTLD-MND patients (9). In previous genetic studies of familial ALS, superoxide dismutase 1 (SOD1) gene mutation was considered to be responsible for ~20% of cases (10,11). It has been reported, however, that TDP-43 is not deposited in spinal cords of familial ALS patients with SOD1 mutations (12,13). These observations suggest that the mechanisms of motor neuron degeneration caused by SOD1 mutations are different from those in sporadic ALS. TDP-43 is also a major component of skein-like inclusions seen in 100% of sporadic ALS cases (14). Thus, it is important to investigate the molecular mechanisms of TDP-43-mediated neurodegeneration in order to understand the pathogenesis and to develop effective treatments for sporadic ALS and other TDP-43 proteinopathies. One of the known biochemical features of TDP-43 deposited in FTLD-U and ALS brains is the presence of truncated TDP-43 fragments (2,3). Recently, using multiple anti-phosphorylated TDP-43 specific antibodies including pS409/410-specific antibodies, we have shown that 18–26 kDa C-terminal fragments of TDP-43 are major constituents of inclusions in FTLD-U and ALS brains (15).

In this study, we investigated the roles of fragmentation and pathogenic mutations of TDP-43 for the formation of Ub-positive inclusions in SH-SY5Y cells. Here we show that expression of TDP-43 C-terminal fragments results in the formation of cytoplasmic inclusions positive for antibodies to phosphorylated TDP-43 and Ub, and incorporation of newly synthesized endogenous full-length TDP-43 into cytoplasmic aggregates of the C-terminal fragments. Expression of fourteen pathogenic ALS mutations so far discovered in the TDP-43 gene shows a propensity to promote intracellular aggregation. Furthermore, using mass spectrometric analysis, we have successfully identified new cleavage sites of C-terminal fragments of TDP-43 deposited in FTLD-U brains.

### RESULTS

**Expression of TDP-43 fragments in SH-SY5Y cells**

To examine whether C-terminal fragments of TDP-43 readily aggregate in neuronal cells, we expressed several kinds of N-terminal and C-terminal fragments of TDP-43 and full-length TDP-43 as GFP-fusions (Fig. 1). Confocal microscopic analysis showed that the fluorescence of GFP-tagged full-length TDP-43 (GFP-TDP WT) was mainly localized in the nuclei (Fig. 2B). This is consistent with the expression pattern of non-tagged wild-type TDP-43 (16), suggesting that the GFP tag did not alter the cellular localization of TDP-43.

When cells were transfected with GFP-TDP 162-414 or GFP-TDP 218-414, round or dot-like cytoplasmic structures with intense GFP fluorescence were found (Fig. 2C–F). These structures were positive for both anti-pS409/410 and anti-Ub antibodies (Fig. 2C–F). Cells expressing GFP-TDP 274–414 (Fig. 2G and H) and GFP-TDP 315–414 (Fig. 2I and J), on the other hand, showed diffuse GFP staining and pS409/410-positive but Ub-negative inclusion-like structures. We previously reported the presence of such pS409/410-positive and Ub-negative inclusion-like structures. We previously reported the presence of such pS409/410-positive and Ub-negative inclusions in the brains of FTLD-U and ALS cases (15). The expression of these all C-terminal fragments was found in cytoplasm by analyses using confocal microscopy (Fig. 2) and biochemical fractionation (Supplementary Material, Fig. S1A), because they lacks nuclear localization signal (16,17). Taken together, these results indicate that cytoplasmic expression of C-terminal
fragments of TDP-43 results in the formation of intracellular aggregates similar to those found in diseased brains.

N-terminal fragments of GFP-TDP-43 were also expressed in SH-SY5Y cells and analyzed using confocal microscopy and biochemical fractionation. As shown in Fig. 3A, irregularly shaped cytoplasmic structures with strong GFP fluorescence, which are partially positive for Ub, were observed in cells expressing GFP-TDP 1–161. Only a few aggregates positive for Ub were observed in cells transfected with GFP-TDP 1–217 (Fig. 3B). Since these fragments lack the epitope for anti-pS409/410, the phosphorylation state of these structures could not be determined by immunohistochemistry. None of the cells transfected with other N-terminal fragments had any Ub-positive inclusion-like structures (Fig. 3C and D). The results of biochemical fractionation showed that the amount of these N-terminal fragments was greater in the cytoplasm than in the nucleus, while that of GFP-TDP WT was greater in the nucleus than in the cytoplasm (Supplementary Material, Fig. S1A). These results suggest that truncations of TDP-43 C-terminal regions affect normal targeting of TDP-43 to nuclei. This observation is in good agreement with the previous report by Ayala et al. (18).

Since intracellular inclusion-like structures showed the highest-intensity GFP signals in Figs 2 and 3, they were able to be selectively detected by reducing the laser power at 488 nm. Quantitative analyses under such analytical conditions clearly indicated that significantly a larger number of intracellular aggregates were formed in cells expressing GFP-TDP 162–414, GFP-TDP 218–414 and GFP-TDP 1–161 than in cells expressing GFP-TDP WT (Fig. 3E).

Figure 4 shows the results of immunoblot analyses of cell lysates using anti-GFP, a commercially available phosphorylation-independent anti-TDP-43 (ProteinTech), and anti-pS409/410 antibodies. Anti-TDP-43 detected endogenous TDP-43 at 43 kDa, exogenous full-length TDP-43, all N-terminal fragments and GFP-TDP 162–414, but did not GFP-TDP 218–414, 274–414 and 315–414 (Fig. 4A and D). These results suggest that the epitopes of this antibody are located in the N-terminal region between 1 and 217 residues. Anti-GFP antibody stained all the exogenous TDP-43
TDP-43 has been reported to regulate the alternative splicing of exon 9 of cystic fibrosis transmembrane conductance regulator (CFTR) transcripts (20). TDP-43 is capable of binding to a (UG)nUm element in CFTR intron 8 near its junction with exon 9. Through this binding, TDP-43 enhances the exon skipping of exon 9 during CFTR splicing. To evaluate the functional significance of TDP-43 fragments used in this study, we performed CFTR exon 9 skipping assay (16). We co-transfected the expression plasmid of TDP-43 wild-type or fragments with the reporter plasmid pSPL3-CFTR9 (including a TG11T7 polymorphic locus) (16) into SH-SY5Y cells. The transcripts with and without the CFTR exon 9 insert are expected to be 360 and 177 bp long, respectively (16), and these were analyzed by RT–PCR. As shown in Fig. 5, mRNA from cells transfected with empty vector pEGFP gave only one RT–PCR band of 360 bp, while that from cells transfected with TDP-43 wild-type gave two RT–PCR bands, 360 and 177 bp, showing that skipping of CFTR exon 9 was increased by expression of GFP-TDP WT. We also confirmed that the GFP portion did not affect the CFTR exon skipping activity of TDP-43. All mRNAs from cells co-transfected with the C-terminal fragments showed one RT–PCR band of 360 bp (Fig. 5A). Of the four mRNAs from cells co-transfected with the N-terminal fragments, mRNA from GFP-TDP 1–161 showed a band of 360 bp, while the others showed two bands of 360 and 177 bp (Fig. 5B). These results indicate that the fragments without
the entire RRM-1 motif do not have exon skipping activity, while the wild-type and fragments with the RRM-1 motif have the activity (Figs 1 and 5). These results are in good agreement with the observation by Buratti and Baralle (21) that the RRM-1 domain is necessary for binding with RNA. It is noteworthy that all the TDP-43 fragments which form intracellular aggregates lack exon skipping activity.

Expression of TDP-43 C-terminal fragment facilitates aggregation of full-length TDP-43 in SH-SY5Y cells

To test whether C-terminal fragments of TDP-43 interact with full-length TDP-43, C-terminal fragments of GFP-TDP-43 were co-expressed with full-length DsRed-fused TDP-43 (DsRed-TDP-43) in SH-SY5Y cells. Immunoprecipitation experiments of cell lysates using agarose conjugated anti-GFP followed by immunoblotting with anti-RFP or anti-TDP-43 showed that GFP-TDP-43 C-terminal fragments as well as full-length GFP-TDP-43 were bound to full-length DsRed-TDP-43 (Fig. 6). Full-length GFP-TDP-43 was found to more strongly interact with DsRed-TDP-43 than any other C-terminal fragments of GFP-TDP-43. The experiments also showed a weak but notable interaction between endogenous TDP-43 and full-length GFP-TDP-43 or C-terminal fragments of GFP-TDP-43. These results suggest that both full-length GFP-TDP-43 and its C-terminal fragments interact not only with full-length DsRed-TDP-43 but also with endogenous TDP-43 in SH-SY5Y cells.

To monitor the intracellular interaction between endogenous TDP-43 and C-terminal fragments of GFP-TDP-43, SH-SY5Y cells were transfected with GFP-TDP-162–414 or GFP-TDP-218–414 and analyzed by confocal microscopy. Immunostaining using anti-TDP-43 showed that full-length GFP-TDP-43 was co-localized with endogenous TDP-43 in nuclei (Fig. 7A). We observed that GFP signals from cytoplasmic inclusions of GFP-TDP 162–414 or GFP-TDP 274–414 were overlapped with immunoreactivities of anti-TDP-43. Furthermore, immunoreactivities of anti-TDP-43 were almost eliminated from the nuclei of these cells (Fig. 7B and C). When full-length GFP-TDP-43 was co-expressed with full-length DsRed-TDP-43, both proteins were found to be localized in nuclei with no formation of inclusion-like structures (Fig. 7D). In contrast, round cytoplasmic inclusions with both GFP and DsRed signals appeared when GFP-TDP 162–414 (Fig. 7E) or GFP-TDP 274–414 (Fig. 7F) was co-expressed with full-length DsRed-TDP-43. These results indicate that endogenous TDP-43 or exogenous full-length DsRed-TDP-43 is trapped into cytoplasmic inclusions formed by GFP-TDP 162–414 or GFP-TDP 218–414, which is consistent with the results of immunoprecipitation experiments shown in Fig. 6.

Effects of pathogenic mutations on aggregation of TDP-43

Then, we tested the effect of mutations of the TDP-43 gene found in familial and sporadic ALS cases on the intracellular aggregates of C-terminal fragments of GFP-TDP-43 (GFP-TDP 162–414). GFP-TDP 162–414 with or without mutations was expressed in SH-SY5Y cells, which were then analyzed by immunoblot and confocal microscopy. We first confirmed almost same expression levels of all exogenous
GFP-TDP 162–414 with or without mutations by immunoblot analysis with anti-TDP-43 (Fig. S2). Figure 8 showed that all 14 mutant GFP-TDP 162–414 formed more intracellular aggregates than wild-type GFP-TDP 162–414. Of these mutations, the number of cells with aggregates was significantly higher in GFP-TDP 162–414 with D169G, G294A, Q331K, M337V, Q343R, N390D and N390S, when compared with the wild-type GFP-TDP 162–414 (Fig. 8B).

When full-length TDP-43 with or without GFP fusion was expressed in cells, we could not find any significant difference in the number of cells with aggregates between wild-type and all mutants (data not shown). Furthermore, there was no significant difference in the generation of TDP-43 fragments (Supplementary Material, Fig. S3) or exon skipping activity of CFTR exon 9 between wild-type full-length TDP-43 and mutated full-length TDP-43 (data not shown).

Identification of the cleavage sites of N-terminally truncated TDP-43 fragments in FTLD-U brains

To identify the cleavage sites of the C-terminal fragments of TDP-43 deposited in brains of FTLD-U patients, we performed protein chemical analyses of the major fragments of 18–26 kDa in the Sarkosyl-insoluble fraction (Fig. 9A). Mass spectra analysis of tryptic digests of these fragments identified two typical tryptic peptides, (K)GISVHISNAEPKHSNSR (residues 252–268) and (R)FGGNPGFGQNGGFGNSR (residues 276–293), and two unusual tryptic peptides, (M)DVFIPKPFR (residues 219–227) (Fig. 9B) and (E)DLIIK (residues 247–251) (Fig. 9C). N-termini of the latter two peptides are not produced by trypsin, because this enzyme cannot cleave Met218-Asp219 and Glu246-Asp247 bonds. These results suggest that these peptides are N-terminal parts of C-terminal fragments of TDP-43, and that the major C-terminal fragments deposited in FTLD-U brains are produced by cleavage between Met218-Asp219 or Glu246-Asp247.

To characterize these C-terminal fragments of TDP-43 deposited in FTLD-U brains with regards to intracellular aggregates formation, phosphorylation, and CFTR exon 9 splicing activity, GFP-TDP 219–414 and GFP-TDP 247–414 were constructed and expressed in SH-SY5Y cells for 3 days. These cells were analyzed using confocal microscopy, immunoblot and CFTR exon 9 skipping assay. As shown in Fig. 10A, round cytoplasmic inclusions with GFP fluorescence were clearly observed in cells expressing GFP-TDP 219–414 or GFP-TDP 247–414. These were also positive for anti-pS409/410 and anti-Ub. In immunoblot analyses, GFP-TDP 219–414 and GFP-TDP 247–414 were detected in Sar-soluble and insoluble fractions with anti-pS409/410 (Fig. 10B). These results suggest that these C-terminal fragments have high propensity to aggregate in cells, which is in good agreement with above results obtained from cells expressing other C-terminal fragments (e.g. GFP-TDP 218–414). Furthermore, expression of each C-terminal fragment resulted in a decrease in exon 9 skipping activity relative to GFP-TDP wild-type, as shown in Fig. 10C. We also found that overexpression of these C-terminal fragments led to a slight but
significant increase in CFTR exon 9 inclusion (Fig. 10C, lower panel). This result suggests that endogenous TDP-43 was trapped with these aberrant C-terminal fragments, resulting a loss of exon 9 exclusion activity by endogenous TDP-43.

DISCUSSION

In this work, we showed that expression of C-terminal and N-terminal fragments of TDP-43 as GFP fusions resulted in the formation of phosphorylated and ubiquitinated aggregates in cultured cells. We first tried to express non-tagged C-terminal TDP-43 fragment (residues 162–414 or 218–414) in SH-SY5Y cells, but without success (data not shown). We then constructed plasmids encoding GFP-tagged N-terminal and C-terminal fragments of TDP-43, as shown in Fig. 1. The C-terminal fragments were significantly more prone to aggregate than full-length TDP-43. These aggregated C-terminal fragments were phosphorylated at Ser409 and Ser410, and were recovered in the TX-insoluble and Sar-soluble as well as Sar-insoluble fractions. These features are consistent with our previous findings, which showed that phosphorylated C-terminal fragments of TDP-43 were the major component of Sar-insoluble TDP-43 in the FTLD-U and ALS brains (15).

Recently, Johnson et al. (22) reported a yeast TDP-43 proteinopathy model. They found that RRM2 and a C-terminal region (188–414 residues) are required for TDP-43 to form toxic aggregates. The fact that the highest propensity to aggregate was seen with GFP-TDP 162–414 and GFP-TDP 218–414 in the present study is consistent with their observations. However, the formation of pS409/410-positive inclusion-like structures in cells expressing C-terminal fragments without RRM2 (GFP-TDP 274–414 and 315–414), and the lack of striking cell death in cells expressing any GFP-tagged TDP-43 fragments (data not shown), differ from their findings. Furthermore, we could not detect intracellular aggregates formed by full-length GFP-TDP-43 in this study. One of the reasons for such discrepancies may be the differences between cultured neuronal cells and yeast.

We also found that one of the N-terminal fragments of TDP-43, GFP-TDP 1-161 were also prone to aggregate in cultured cells. This fragment was recovered in the TX-insoluble and Sar-soluble fraction. Previous reports indicated that lower-molecular-weight bands were present in the Sar-insoluble fractions of FTLD-U cases using the anti-TDP-43 (ProteinTech) (2,3,23). In this study, we established that this antibody recognizes the epitopes in the N-terminal portion between the residues 1 and 217 but not the C-terminal portion. Therefore, N-terminal fragments of TDP-43 may be present in the Sar-insoluble fraction of FTLD-U samples. It is noteworthy, therefore, that the expression of N-terminal TDP-43 fragments, as well as C-terminal fragments, could cause the formation of cytoplasmic aggregates in cultured cells.

The results of co-expression experiments using GFP-TDP 162–414 or GFP-TDP 218–414 and full-length DsRed-TDP-43 (Fig. 7) are consistent with the notion that cytoplasmic aggregates of C-terminal fragments of TDP-43 initially formed recruit newly synthesized full-length TDP-43 monomer and stay it in cytoplasm, resulting in depleting normal nuclear TDP-43. This may explain why normal TDP-43 staining is cleared in nuclei of diseased neurons containing cytoplasmic TDP-43 aggregates. Such mislocalization of full-length TDP-43 may induce neuronal dysfunction due to loss of
physiological functions of TDP-43 in nuclei (3,17). In this study, we showed that expression of aberrant C-terminal fragment (GFP-TDP WT), GFP-TDP 162–414 or each of 14 mutants (D169G, G287S, G290A, G294A, G298S, A315T, Q331K, M337V, Q343R, G348C, R361S, A382T, N390D and N390S) for 3 days, fixed and analyzed by confocal microscopy. DNA was stained with TO-PRO-3. (A) Images from cells transfected with GFP-TDP WT, GFP-TDP 162–414, GFP-TDP 162–414 with D169G (D169G), G294A (G294A), A382T (A382T) and Q343R (Q343R) were shown. (B) The rates of cells including intracellular aggregates were calculated in arbitrary units. Fluorescence intensity within an area of ~800 × 800 μm was assessed by confocal microscopy. The intensity of GFP was calculated as a ratio to that of TO-PRO-3. More than eight areas per sample were measured (n = 8–16). Data are means ± SEM. *P < 0.05; **P < 0.01 by Student’s t-test against the value of GFP-TDP 162–414.

Interestingly, all TDP-43 fragments which form cytoplasmic aggregates lack CFTR exon 9 skipping activity (Figs 1 and 5). It was reported that the entire RRM-1 domain and C-terminal glycine-rich domain are required for CFTR exon 9-positive ~23 kDa bands (an arrow) were dissected and digested in-gel with trypsin. (B and C) Product ion spectra of a mass signal (M+2H)2+ of m/z 560.55 (B) and m/z 601.71 (C) from tryptic digests of urea-soluble C-terminal fragment of TDP-43 from FTLD-U brains. These spectra show the b and y ion series, identifying the peptide, DVFIPKPFRR (residues 219–227) and DLIIK (residues 247–251), respectively. Vertical bars denote consecutive mass signals in b and y series.
Several groups have recently reported increased accumulation of TDP-43 fragments in the brain homogenates (8) and cultured cells (5,6) in some of the pathogenic mutations in ALS. The major component of abnormally accumulated TDP-43 is the C-terminal fragments in all TDP-43 proteinopathy (15,23). In this study, however, immunoblot analyses using a commercial TDP-43 antibody and our C-terminal 405–414 antibody (15,19) failed to show any significant differences in the generation of fragments of TDP-43 with or without various mutations (Supplementary Material, Fig. S3). The results of this study provide evidence, for the first time, that all 14 mutations tested consistently enhance aggregation of TDP-43 if they are present in the C-terminal fragments. We examined the effects of TDP-43 mutations on aggregates formation of both GFP-TDP 162–414 and GFP-TDP 218–414. We found that mutations significantly facilitate the formation of cytoplasmic inclusions of GFP-TDP 162–414, but not GFP-TDP 218–414 (data not shown). In this study, GFP-TDP 218–414 was found to be most prone to aggregate in SH-SY5Y cells. Thus, it seems likely that the high propensity to aggregate formation of GFP-TDP 218–414 may mask mutation effects on aggregates formation of GFP-TDP 218–414. So, we speculate that mutation effects were significantly detected in the experiments using GFP-TDP 162–414 which was less prone to form cytoplasmic inclusions than GFP-TDP 218–414. It seems reasonable to speculate that pathogenic mutations and N-terminal truncation synergistically promote abnormal accumulation of TDP-43. Failure to form aggregates in cells that express mutated full length TDP-43 suggests that the cell culture models recapitulate in vivo diseases only partially and that such models need N-terminal truncation of TDP-43 as a prerequisite for the mutation effect.

Igaz et al. (27) reported the cleavage site at Arg 208 in a pathological TDP-43 C-terminal fragment from FTLD-U brains and inclusion formation in cultured cells expressing resultant C-terminal fragment (residues 208–414). In the present study, by mass spectrometric analysis of the sarkosyl-insoluble fraction extracted from the FTLD-U brains, we newly identified two C-terminal fragments generated by N-terminal truncation at Asp219 and Asp247 of TDP-43. Failure to form aggregates in cells that express GFP-TDP 218–414. We found that mutations significantly accelerated and ubiquitinated cytoplasmic inclusions were formed in cells expressing GFP-TDP 218–414 or GFP-TDP 247–414. Thus, the generation of aggregation-prone fragments of TDP-43 may play an important role for pathological process of TDP-43 proteinopathy. The N-termini of both identified peptides were Asp residue, suggesting that the protease(s) responsible for the cleavage may show specificity for the N-terminal side of Asp residues. According to the protease to degrade TDP-43, Zhang et al. (28) previously reported the occurrence of caspase cleavage of TDP-43 in cultured cells by the knockdown of progranulin gene. Furthermore, they recently reported the formation of intracellular inclusions immunopositive for phosphorylated TDP-43 and ubiquitin in cells expressing the GFP-tagged C-terminal fragment of TDP-43 (residues 220–414), which is expected to be generated by caspase cleavage (29). In the present study, however, we did not detect VFIPKPFR (residues 220–227), which is predicted to be produced by trypsin digestion of caspase-cleaved TDP-43, in the sarkosyl-insoluble fraction from the FTLD-U brains. These results suggest that caspase may not be the responsible enzyme for generation of
C-terminal fragments of TDP-43 in human brains. Since several abnormal fragments of 18–26 kDa were detected in FTLD-U and ALS with the antibodies to C-terminal region of TDP-43 like anti-pS409/410 (15, 19, 23), it seems reasonable to speculate the presence of the multiple cleavage sites in the middle of TDP-43. Thus, there may be other fragments, the N-termini of which have yet to be identified, and its responsible proteases. Further investigation of the degradation mechanism of TDP-43 might be needed to elucidate the pathogenesis of TDP-43 proteinopathy.

Our findings here provide further support for the idea that accumulation of fragmented TDP-43 plays an important role in TDP-43 proteinopathy. Our cellular models are expected to be useful tools to investigate the pathogenesis of TDP-43 proteinopathy, since they show pathological and biochemical characteristics similar to those of inclusions found in brains of patients, in terms of size, abnormal phosphorylation and ubiquitination.

MATERIALS AND METHODS

Construction of plasmids
To construct N-terminally green fluorescent protein (GFP)- and DsRed-fused TDP-43, a cDNA encoding full-length TDP-43 was amplified from pcDNA3-TDP-43 vector using the following primers: GFP/DSRed-forward, 5'-CCGCTGAGCTATGTCACAGCGACATATGA-3' and GFP/DSRed-reverse, 5'-CGGGATCCCTACATTCCCCACCCAGCAGAG-3'. The amplified fragment was digested with Xho I/Bam HI and was cloned into the same cleavage sites of the pEGFP-C1 vector (Clontech) and pDsRed-Monomer-C1 vector (Clontech), respectively. For the construction of GFP-tagged TDP-43 fragments, each fragment was amplified by PCR using the following primers: GFP/DSRed-forward, 5'-CCGCTGAGCTATGTCACAGCGACATATGA-3' and GFP/DSRed-reverse; for GFP-TDP 162–414, forward, 5'-CGGGATCCCTACATTCCCCACCCAGCAGAG-3' and reverse, 5'-CGGGATCCCTACACATCCCCGTACTGAG-3'; for GFP-TDP 1–217, GFP/DSRed-forward and reverse, 5'-CGGGATCCCTACATTCCCCACCCAGCAGAG-3' and reverse, 5'-CCGCTGAGCTATGTCACAGCGACATATGA-3'; for GFP-TDP 1–314, GFP/DSRed-forward and reverse, 5'-CGGGATCCCTACATTCCCCACCCAGCAGAG-3' and reverse, 5'-CCGCTGAGCTATGTCACAGCGACATATGA-3'; for GFP-TDP 218–414, forward, 5'-CGGGATCCCTACATTCCCCACCCAGCAGAG-3' and reverse, 5'-CCGCTGAGCTATGTCACAGCGACATATGA-3'; for GFP-TDP 247–414, forward, 5'-CCGCTGAGCTATGTCACAGCGACATATGA-3' and reverse, 5'-CCGCTGAGCTATGTCACAGCGACATATGA-3'; for GFP-TDP 1–273, GFP/DSRed-forward and reverse, 5'-CCGCTGAGCTATGTCACAGCGACATATGA-3' and reverse, 5'-CCGCTGAGCTCGAGCTGCGTTCAGCATTAATCCAGCCAT-3'; for GFP-TDP 1–217, GFP/DSRed-forward and reverse, 5'-CCGCTGAGCTATGTCACAGCGACATATGA-3' and reverse, 5'-CCGCTGAGCTCGAGCTGCGTTCAGCATTAATCCAGCCAT-3'; for GFP-TDP 1–161, GFP/DSRed-forward and reverse, 5'-CCGCTGAGCTATGTCACAGCGACATATGA-3' and reverse, 5'-CCGCTGAGCTATGTCACAGCGACATATGA-3'; for GFP-TDP 1–273, GFP/DSRed-forward and reverse, 5'-CCGCTGAGCTATGTCACAGCGACATATGA-3' and reverse, 5'-CCGCTGAGCTATGTCACAGCGACATATGA-3'; for GFP-TDP 1–217, GFP/DSRed-forward and reverse, 5'-CCGCTGAGCTATGTCACAGCGACATATGA-3' and reverse, 5'-CCGCTGAGCTATGTCACAGCGACATATGA-3'. The resulting products were digested with Xhol/BamHI and were cloned into the same cleavage sites of the pEGFP-C1 vector (Clontech). Site-directed mutagenesis of GFP-tagged or non-tagged full-length TDP-43 and GFP-tagged C-terminal fragment (GFP-TDP 162–414) was carried out to substitute Asp169 to Gly (D169G), Gly287 to Ser (G287S), Gly290 to Ala (G290A), Gly294 to Ala (G294A), Gly298 to Ser (G298S), Ala315 to Thr (A315T), Gln331 to Lys (Q331K), Met337 to Val (M337V), Gln343 to Arg (Q343R), Gly348 to Cys (G348C), Arg361 to Ser (R361S), Ala382 to Thr (A382T), Asn390 to Asp (N390D) and Asn390 to Ser (N390S) using a site-directed mutagenesis kit (Strategene). All constructs were verified by DNA sequencing.

Antibodies
A polyclonal TDP-43 antibody 10782-1-AP (anti-TDP-43) was purchased from ProteinTech Group Inc. A polyclonal antibody specific for phosphorylated TDP-43 (anti-pS409/410) and anti-405-414 antibody specific for C-terminal TDP-43 were prepared as described (15, 19). Anti-ubiquitin monoclonal antibody (mAb), MAB1510, was purchased from Chemicon. Anti-GFP mAb, anti-RFP polyclonal antibody and agaroase-conjugated anti-GFP were purchased from MBL (Nagoya, Japan). Monoclonal anti-alpha-tubulin and anti-p84 were obtained from Sigma and Abcam, respectively.

Cell culture and expression of plasmids
SH-SY5Y cells were cultured in DMEM/F12 medium (Sigma) supplemented with 10% (v/v) fetal calf serum, penicillin–streptomycin–glutamine (Gibco), and MEM Non-Essential Amino Acids Solution (Gibco). The cells were maintained at 37°C under a humidified atmosphere of 5% (v/v) CO2. They were grown to 50% confluence in six-well culture dishes for transient expression and then transfected with expression plasmids using FuGENE6 (Roche) according to the manufacturer’s instructions. Under our experimental conditions, the efficiency of transfection with pEGFP-C1 vector was 20–30%.

Confocal immunofluorescence microscopy
SH-SY5Y cells were grown on a coverslip (15 × 15 mm) and transfected with expression vector(s) (1 or 2 μg). After incubation for the indicated time, the transfected cells on the coverslips were fixed with 4% (w/v) paraformaldehyde in phosphate-buffered saline (PBS) for 30 min. The coverslips were further incubated for 30 min at 37°C to stain nuclear DNA, and analyzed using an LSM5 Pascal confocal laser microscope (Carl Zeiss). Intracellular aggregates of GFP-tagged TDP-43 fragments had much more intense fluorescence of GFP than diffusely expressed, GFP-tagged wild-type TDP-43 or GFP alone. Therefore, to quantify the cells with GFP-tagged TDP-43 aggregates, the laser power (at 488 nm for detection of GFP) was adjusted so that only the aggregates were detected (30).
Total intensity of GFP fluorescence detected at the threshold laser power and that of TO-PRO-3 fluorescence, the latter corresponding to the total number of cells, in a given field (~800 x 800 µm) were measured with LSM5 Pascal v 4.0 software (Carl Zeiss) and the ratios of cells with inclusions were calculated.

In the co-expression experiments with combinations of GFP-tagged TDP 162–414 or TDP 218–414 and DsRed-tagged wild-type TDP-43, the laser power (at 543 nm for detection of DsRed) was appropriately adjusted so that the signals did not overlap.

**Sequential extraction of proteins and immunoblotting**

SH-SY5Y cells were grown in six-well plates and transfected transiently with expression plasmids (1 µg). After incubation for the indicated time, cells were harvested and lysed in TS buffer [50 mM Tris–HCl buffer, pH 7.5, 0.15 M NaCl, 5 mM ethylenediaminetetraacetic acid (EDTA), 5 mM ethylene glycol bis (β-aminoethyl ether)-N,N,N,N-tetraacetic acid (EGTA) and protease inhibitor cocktail (Roche)]. The lysates were centrifuged at 290 000g for 20 min at 4°C, and the supernatant was recovered as the TS-soluble fraction. The TS-insoluble pellets were lysed in TS buffer containing 1% (v/v) Triton X-100 (TX) and centrifuged at 290 000g for 20 min at 4°C. The supernatant was collected as the TX-soluble fraction. The TX-insoluble pellets were further sonicated in TS buffer containing 1% (w/v) Sarkosyl (Sar) and incubated for 30 min at 37°C. The mixtures were centrifuged at 290 000g for 20 min at room temperature and the supernatant was recovered as the Sar-soluble fraction. The remaining pellets (insoluble in Sar) were lysed in SDS-sample buffer and heated for 5 min.

Subcellular fractionation was performed using NE-PER nuclear and cytoplasmic extraction reagents (Pierce) according to the manufacturer’s instructions. SH-SY5Y cells were grown in six-well plates and transfected transiently with expression plasmids (1 µg). After incubation for 48 h, cells were harvested and fractionated into nuclear and cytoplasmic fraction using NE-PER.

Protein concentration was estimated using the BCA Protein Assay Kit (Pierce). Each sample (10 or 20 µg) was separated by 10 or 12% (v/v) SDS–PAGE using Tris–glycine buffer and system, and proteins were transferred onto polyvinylidene difluoride membrane (Millipore). The blots were blocked with 3% (v/v) gelatin and incubated overnight with the indicated primary antibody in 10% (v/v) calf serum at an appropriate dilution (1:1000–5000) at room temperature. The membranes were washed and then incubated with a biotin-labeled secondary antibody (Vector) for 2 h or a horse radish peroxidase-labeled secondary antibody (BIO-RAD) for 1 h at room temperature. Signals were detected using the ABC staining kit (Vector) or ECL Plus Western Blotting Detection System (GE Healthcare).

**CFTR exon 9 skipping assay**

Cos-7 cells grown in six-well plates were transfected with 0.5 µg of the reporter plasmid pSPL3-CFTR9 (including a TG11T7 (16) or TG13T5 sequence) plus 1 µg of pEGFP plasmid encoding wild-type TDP-43 or its fragment, using FuGENE6. The cells were harvested 48 h post-transfection and total RNA was extracted with TRizol (Invitrogen). The cDNA was synthesized from 1 µg of total RNA with the use of the Superscript II system (Invitrogen). Primary and secondary PCRs were carried out according to the instruction manual of the exon trapping system (Life Technologies).

**Immunoprecipitation**

SH-SY5Y cells grown in six-well plates were transfected with expression vectors (total 2 µg). After incubation for 3 days, cells were harvested and lysed in RIPA buffer [50 mM Tris–HCl buffer, pH 7.5, 0.15 M NaCl, 1% NP-40, 0.5% deoxycholic acid Na, 0.1% SDS, 5 mM EDTA, 5 mM EGTA, 1 mM PMSF and protease inhibitor cocktail (Roche)]. The lysates were centrifuged at 20 400g for 10 min at 4°C and the supernatant (total protein: ~100 µg) was recovered and subjected to IP with agarose conjugated anti-GFP [20 µl of 50% gel slurry (~5 µg of anti-GFP, MBL)]. Bound proteins were washed with RIPA buffer and then eluted from the beads with SDS sample buffer. Each sample was separated by 10% SDS–PAGE and immunoblotted with anti-GFP mAb (MBL), anti-RFP polyclonal antibody (MBL) and anti-TDP-43 (ProteinTech).

**Mass spectrometric analysis of C-terminal fragments of TDP-43**

Sarkosyl-insoluble, 8 M urea soluble fractions prepared from the brain of patients with FTLD-U were subjected to reversed phase-HPLC on an Aquapore RP-300 column (4.6 x 30 mm, Brownlee columns) and fractionated samples were immunoblotted with anti-pS409/410. The positive fraction was lyophilized, treated with SDS-sample buffer and loaded on 15% SDS–PAGE. The pS409/410-positive ~23 kDa bands (Fig. 9A) were dissected and digested in-gel with trypsin. The digests were applied to the Paradigm MS4 HPLC system (Microm BioResources). A reversed phase capillary column (Develosil ODS-HG5, 0.075 x 150 mm, Nomura Chemical) was used at a flow rate of 300 nm/min with a 4–80% linear gradient of acetonitrile in 0.1% formic acid. Eluted peptides were directly detected with an ion trap mass spectrometer, LXQ (Thermo Electron). The obtained spectra were analyzed with BioWorks (Thermo Electron) and Mascot (Matrix Science).

**Statistical analysis**

The P-values for the description of the statistical significance of differences were calculated by means of the unpaired, two-tailed Student’s t-test using Prism 4 software.

**SUPPLEMENTARY MATERIAL**

Supplementary Material is available at HMG online.

**ACKNOWLEDGEMENTS**

We thank Dr H. Mimuro (University of Tokyo) for helpful advice and discussions.
Conflict of Interest statement. None declared.

FUNDING
This work was supported by a Grant-in-Aid for Scientific Research on Priority Areas—Research on Pathomechanisms of Brain Disorders (to M.H., 200223038), and Grants-in-Aid for Scientific Research to M.H. (18300117) and F.K. (20300144) and to T.N. (19590297) and T.A. (19591024) from the Ministry of Education, Culture, Sports, Science and Technology of Japan.

REFERENCES


